• 1
    Presti JC Jr. Neoplasms of the prostate gland. In: TanagoEA, Mc AninchJW (eds). Smith's General Urology, 15th edn, Middle East edition. McGraw-Hill, Beirut, Lebanon, 2000; 399406.
  • 2
    Roehrborn CG, McConnell JD, Barry MJ et al. A quick reference for urologists. Benign prostatic hyperplasia update. Recommendations from the guideline panel. AUA 2003; 113.
  • 3
    Jensen KM-E, Jorgensen JB, Mogensen P. Urodynamics in prostatism: I. Prognostic value of uroflowmetry. Scand. J. Urol. Nephrol. 1988; 22: 10917.
  • 4
    Chancellor MB, Yoshimura N. Voiding function and dysfunction. Physiology and pharmacology of the bladder and urethra. In: WalshPC, RetikAB, VaughanEDJr, WeinAJ (eds). Campbell's Urology, 8th edn, vol. 2, sect. 23. WB Saunders Co., Philadelphia, PA, 2002; 8291734.
  • 5
    Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J. Urol. 2004; 172: 206.
  • 6
    Littrup PJ, Lee F, Borlaza GS. Percutaneous ablation of the canine prostate using transrectal U/S guidance absolute ethanol. Invest. Radiol. 1988; 23: 734.
  • 7
    Plante MK, Gross AL, Kliment J, Kinder M, Zvara P. Intraprostatic ethanol chemo ablation via transurethral and transperineal injection. BJU Int. 2003; 91: 948.
  • 8
    Goya N, Ishikawa N, Ito F et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J. Urol. 1999; 162: 3836.
  • 9
    Ditrolio J, Patel P, Watson RA, Irwin RJ Jr. Chemo ablation of the prostate with dehydrated alcohol for treatment of prostatic obstruction. J. Urol. 2002; 167: 21004.
  • 10
    Wasson JH, Reda DJ, Bruskewitz RC. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N. Engl. J. Med. 1995; 332: 759.
  • 11
    Wheelahan J, Scott NA, Cartmill R et al. Minimally invasive non-laser thermal techniques for prostatectomy: a systematic review. BJU Int. 2000; 86: 97788.
  • 12
    Nau WH Jr, MilamDF, RoseliRJ. Principles of laser therapy. In: NarayanP (ed.). Benign Prostatic Hyperplasia. Churchill Livingstone, London, 2000; 2219.
  • 13
    Angell JC. Treatment of benign prostatic enlargement by phenol injection. Br. J. Urol. 1969; 41: 7358.
  • 14
    Mebust WK, Holtgrewe HL, Cockett AT. Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J. Urol. 1989; 141: 2437.
  • 15
    Nesbit RM. A history of transurethral prostatectomy. Rev. Mex Urol. 1975; 35: 34962.
  • 16
    Savoca G, De stefani S, Gattuccio I, Paolinelli D, Stacul F, Belgrano E. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: Preliminary report. Eur. Urol. 2001; 40: 5048.
  • 17
    Broughton AC, Smith PH. The significance of perineal pain after injection of the prostate. B. J. Urol. 1970; 42: 735.
  • 18
    Harmon WJ, Barrett DM, Qian J, Lauvetz RW, Bostwick DG, Gocken M. Transurethral enzymatic ablation of the prostate: canine model. Urology 1996; 48: 22933.
  • 19
    Livraghi T, Giorgio A, Marin G. Hepatocellular carcinoma and cirrhosis in 746 patients long-term results of percutaneous ethanol injection. Radiology 1995; 197: 1018.
  • 20
    Bennedbæk FN, Nielsen LK, Hegedüs L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-Thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J. Clin. Endocrinol. Metabol. 1998; 83: 8305.
  • 21
    Solbiati L, Giangrande A, De Pra L, Bellotti E, Cantu P, Ravetto C. Percutaneous ethanol injection of parathyroid tumors under US guidance: treatment for secondary hyperparathyroidism. Radiology 1985; 155: 60710.
  • 22
    Munk PL, Marotta TR. Intralesional injection of absolute alcohol into vertebral hemangiomas: a new treatment option? Am. J. Neuroradiol. 1999; 20: 95960.
  • 23
    Takaoka K, Inoue S, Ohira S. Central bronchopleural fistulas closed by bronchoscopic injection of absolute ethanol. Chest 2002; 122: 3748.
  • 24
    Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J. Ultrasound. Med. 1998; 17: 5313.
  • 25
    Plante MK, Bunnell ML, Trotter SJ, Jackson TL, Esenler AC, Zvara P. Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radio-frequency energy and ethanol. Prostate Cancer Prostat. Dis. 2002; 5: 1838.
  • 26
    Grisea P, Planteb M, Palmerc J et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur. Urol. 2004; 46: 496502.
  • 27
    Badlani G, Gilling P, Ditrolio J. Transurethral ethanol ablation of the prostate (TEAP): data review and discussion. 19th World Congress on Endourology, Bangkok, Thailand, November 147, 2001.